Aurobindo gets US nod for Ciprofloxin tablets
Aurobindo Pharmaceuticals on Tuesday said it has got USFDA approval for its Ciprofloxacin tablets in 250mg, 500mg and 750mg strengths instead of Cefpodoxime Proxetil as announced earlier.
By PTI |
MUMBAI: Aurobindo Pharmaceuticals on Tuesday said it has got USFDA approval for its Ciprofloxacin tablets in 250mg, 500mg and 750mg strengths instead of Cefpodoxime Proxetil as announced earlier.
In a filing to the Bombay Stock Exchange, Aurobindo Pharma said, "The company regrets its earlier announcement of Cefpodoxime Proxetil approval, which was displayed by the FDA. However, this product is still waiting for the official approval."
Besides, the drug that got the approval, Ciprofloxacin belongs to the class of floroquinolones and is the generic international name for the synthetic microbicide, manufactured and sold by Bayer Pharmaceutical under the brand names Cipro, Ciproxin and Ciprobay, the company said in the statement.
Ciprofloxacin enjoys a market of over Rs 925 crore (US 230 million dollar) in the US.
In a filing to the Bombay Stock Exchange, Aurobindo Pharma said, "The company regrets its earlier announcement of Cefpodoxime Proxetil approval, which was displayed by the FDA. However, this product is still waiting for the official approval."
Besides, the drug that got the approval, Ciprofloxacin belongs to the class of floroquinolones and is the generic international name for the synthetic microbicide, manufactured and sold by Bayer Pharmaceutical under the brand names Cipro, Ciproxin and Ciprobay, the company said in the statement.
Ciprofloxacin enjoys a market of over Rs 925 crore (US 230 million dollar) in the US.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
